Globe Newswire (Tue, 2-Jun 4:05 PM ET)
Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
Globe Newswire (Tue, 2-Jun 4:55 AM ET)
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
Globe Newswire (Fri, 22-May 4:05 PM ET)
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 7-May 4:05 PM ET)
Globe Newswire (Mon, 27-Apr 5:13 PM ET)
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer
Globe Newswire (Wed, 15-Apr 2:00 PM ET)
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Globe Newswire (Wed, 8-Apr 4:05 PM ET)
Globe Newswire (Thu, 26-Mar 4:05 PM ET)
Market Chameleon (Wed, 7-Jan 2:53 AM ET)
Market Chameleon (Mon, 5-Jan 2:55 AM ET)
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Crinetics Pharmaceuticals trades on the NASDAQ stock market under the symbol CRNX.
As of June 5, 2026, CRNX stock price declined to $32.92 with 812,622 million shares trading.
CRNX has a beta of 1.07, meaning it tends to be more sensitive to market movements. CRNX has a correlation of 0.05 to the broad based SPY ETF.
CRNX has a market cap of $3.47 billion. This is considered a Mid Cap stock.
Last quarter Crinetics Pharmaceuticals reported $10 million in Revenue and -$1.23 earnings per share. This beat revenue expectation by $2 million and met earnings estimates .
In the last 3 years, CRNX traded as high as $62.53 and as low as $15.76.
The top ETF exchange traded funds that CRNX belongs to (by Net Assets): VTI, VB, IWM, VBK, VXF.
CRNX has underperformed the market in the last year with a price return of +2.5% while the SPY ETF gained +25.0%. CRNX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.7% and -11.2%, respectively, while the SPY returned +7.9% and -0.7%, respectively.
CRNX support price is $33.55 and resistance is $35.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRNX shares will trade within this expected range on the day.
